World’s First Submarine Desalination Facility to Begin Clean Water Production in 2026

Flocean's subsea desalination pod

Flocean Seabed Desalination Pod

Credit: Florshan

Transforming seawater into potable water has been a costly and energy-heavy endeavor for many regions globally. However, a pioneering approach by Flocean, a Norwegian company, is set to revolutionize this process. They aim to unveil the world’s first commercial-scale seabed desalination plant by 2026, significantly slashing both costs and energy consumption.

Global freshwater demand is surging due to factors like population growth, climate change, and industrial needs. Meanwhile, fresh water is increasingly scarce due to droughts, deforestation, and over-irrigation practices.

Currently, terrestrial desalination provides merely 1% of the world’s freshwater supply, with over 300 million people depending on it for their daily needs. The largest plants are located in the Middle East, where low energy costs enhance the feasibility of desalination technologies amid rising water scarcity.

Reverse osmosis is the primary technology employed in desalination today, which entails pressurizing seawater to force it through membranes that only allow water molecules to pass. This process is notoriously energy-intensive.

Flocean’s innovative strategy involves deploying underwater pods that filter seawater at significant depths, enabling separation of freshwater from salt while returning the salt back to the ocean. These reverse osmosis pods take advantage of hydrostatic pressure to filter seawater with reduced energy requirements.

The company asserts that their method can cut energy usage by approximately 40-50% compared to traditional desalination methods. Additionally, the deeper the pods are submerged, the cleaner the seawater, resulting in less pre-treatment before it reaches the membrane. Nikko zone conditions contribute to this purity.

“From a process perspective, it’s relatively straightforward,” states Alexander Fuglsang, Founder and CEO of Flocean. “The salinity, temperature, and pressure conditions remain stable, with minimal bacterial interference that can lead to biofouling.” The hydrostatic pressure also aids in diffusing the brine by-product, which is claimed not to have harmful chemicals for marine ecosystems.

Over the past year, Flocean has been successfully desalinating water at a depth of 524 meters at its test site located at the Mønstad Industrial Park, Norway’s leading marine supply base. The upcoming commercial facility, dubbed Flocean One, is set to produce 1,000 cubic meters of freshwater daily upon its launch next year. This scalable approach allows for the addition of more desalination pods as needed.

“We opt to maintain uniformity within the subsea units while expanding through replication, instead of constantly developing larger machinery,” explains Fugelsang. Nevertheless, scaling introduces engineering challenges, particularly in optimizing power distribution and permeation manifolds for increased efficiency.

This desalination technology has the potential to offer affordable freshwater solutions if properly implemented and costs are minimized, but large-scale viability has yet to be established, notes Nidal Hilal from New York University Abu Dhabi. “Successfully integrating this solution into municipal systems will require overcoming various technological and financial hurdles over time.”

Reducing costs is crucial for wider adoption of this technology, given that traditional water acquisition methods, such as lake or aquifer pumping, remain cheaper. Key expenses for Flocean stem from membrane cleaning and maintenance. Innovations in membrane technology are underway, with Hilal’s research focusing on conductive membranes that electrically repel salt and other contaminants, which may enhance cleanliness and throughput. Efforts are also being made to recycle single-use plastics into membrane materials to boost sustainability and drive down costs. “Durable membranes and high-efficiency pumps can further decrease operational costs, while incorporating renewable energy can lower electricity expenditures,” Hilal adds.

Flocean One is anticipated to start freshwater production in the second quarter of 2026. If all goes as planned, this technology could pave the way for larger plants in different locations. “The greatest challenge lies in achieving the right alignment,” Fugelsang concludes. “We seek clients, government approvals, and robust financial partnerships.”

Topics:

Source: www.newscientist.com

Citizens in Georgia rally against proposed construction of major monkey breeding facility in their community.

Residents are expressing concerns about the facility itself and the potential for monkeys to escape, which has occurred in the past. Similar incidents have been reported at other facilities in the United States, including one operated by Oregon Health & Science University. In Portland, there have been no reports of harm to nearby residents,

“We’re facing a jungle – the noise, the smell, the risk of disease,” stated Penny Reynolds, who resides across the street from the land designated for the Bainbridge facility.

Safer Human Medicine has reassured residents that they take all necessary precautions to ensure that all waste remains on-site and is sent to the city’s wastewater treatment plant, and that most of the noise is contained on-site with no detectable odors.

Greg Westergaard, the CEO of monkey breeder Alpha Genesis, mentioned that establishing a monkey facility entails significant effort.

“It would involve extensive training and infrastructure,” he explained. “There will be unpleasant odors and wastewater from cleaning.”

Residents of Bainbridge point to the backgrounds of several executives at Safer Human Medicine, two of whom previously held leadership roles at companies that were under investigation, as a reason to be skeptical of their efforts.

CEO of Safer Human Medicines, Jim Harkness, is the chief operating officer of Envigo. He recently pleaded guilty. Thousands of dogs were abandoned, leading to a $35 million fine. Former Chief Operating Officer Kurt Derfler has left Charles River Laboratories. The Department of Justice issued a subpoena The probe was part of an inquiry into the potential smuggling of wild monkeys from Cambodia, and Charles River Laboratories stated at the time that any concerns about its involvement were “unwarranted.”

Neither Mr. Harkness nor Mr. Derfler faced individual charges related to those incidents.

Safer Human Medicine declined an interview request. “Envigo was functioning under unprecedented circumstances brought on by the pandemic,” they said in an email. They also stated that “we have been committed to operating responsibly and ethically in this field for decades and will continue to do so.”

Long-tailed macaques, also known as crab-eating macaques, are climbing the pillar in Indonesia in 2023.Chaidir Mahyudin/AFP via Getty Images file

Safer Human Medicine has stated that they do not use wild-caught macaques. Herpes BThe macaques will be sourced from Asia, but the specific location has not been disclosed.

Community activism in Bainbridge has made an impact. What was initially promoted as a “significant investment” is now overseen by Rick McCaskill, executive director of the Bainbridge and Decatur County Development Authority. Approximately $400 million and 260 jobs Things took a turn quickly. Following pushback from the community, Bainbridge leaders decided in February to Withdraw support for the Safer Human Medicine Project.

“The division and fear within the community seemed to outweigh the benefits of the project,” McCaskill remarked.

Monkeys used for research are housed at seven national primate research centers, each with its own breeding colonies, as well as other facilities across the country. While the national primate research centers mostly utilize rhesus macaques, pharmaceutical companies tend to prefer long-tailed macaques, which Safer Human Medicine intends to use.

Animal testing for drug development was formerly mandatory in the United States, but President Joe Biden will lift the ban in 2022. FDA Modernization Act 2.0 Signed into LawAllow non-animal options where possible. Several members of Congress voted this year to The bill was submitted. We advocate for a shift away from animal testing.

“There are various alternatives available today, such as AI, computer models, and organs on chips,” stated Jim Newman, spokesperson for the American Association for Medical Progress, a group that supports animal testing when necessary, “but current options can only reduce the number of animals to a certain extent.”

An artist’s rendering of a monkey enclosure proposed for Bainbridge, Georgia.Safer Human Medicines

Currently, researchers still rely on monkeys for certain tests, and some animal researchers cite a U.S. Shortage of long-tailed macaques — Imports reportedly dropped by over 20% in 2020 due to China halting exports, leading to a surge in prices of long-tailed macaques.

Safer Human Medicine believes that their proposed facility can address the monkey shortage, intending to start with 500 to 1,000 monkeys and then expand. They stated that the facility would be funded by industry and private donors in the US, without specifying them.

The extent of opposition from local residents to the facility remains unclear. Some local politicians who opposed the facility lost recent elections, but it is uncertain if their defeat was linked to their stance.

Nevertheless, Faircloth asserted that her group has no intention of backing down.

“If we don’t stand up for our rights, they will walk all over us,” she declared. “And we can’t allow that to happen.”

Source: www.nbcnews.com

A16z-funded Apex Space inaugurates new facility to increase satellite bus production

when apex space The company, which came out of stealth last October, had the provocative goal of eliminating “new bottlenecks” plaguing the space industry by building satellite buses at scale.

To get there, Apex announced today that it will open a new headquarters and production facility in California and eventually scale up to manufacture 50 satellite platforms per year. Apex CEO Ian Cinnamon said in a statement that the new 46,000-square-foot facility is “vital to meeting customer demand.”

“Our customers want spacecraft with short lead times, and Factory One delivers that,” he said.

Apex wants to disrupt one of the most entrenched parts of the space industry. Satellite buses are generally made to order, which means their costs are very high and delivery times are very long. However, major changes in the industry, such as the reduction in the cost of mass launches into space, have opened up a whole new group of customers looking to send payloads into orbit.

The company plans to initially offer three satellite bus classes. One is a smaller 100 kilogram bus called Aries, which can support a payload of up to 100 kilograms. The motorcoach, called Nova, can accommodate a payload of up to 230 kg. The even larger bus “Comet” can carry up to 500 kilograms. Apex plans to fly the first Aries on SpaceX’s Transporter 10 rideshare mission, scheduled for the first quarter of next year.

Apex aims to expand the factory in the coming years. The company currently plans to deliver five Aries platforms to customers in 2024 and aims to increase production to 20 aircraft by 2025.

The company has raised at least $23.5 million in seed and Series A funding from backers including Andreessen Horowitz and Shield Capital.

Source: techcrunch.com